← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

SRRK logoScholar Rock Holding Corporation(SRRK)Earnings, Financials & Key Ratios

SRRK•NASDAQ
$47.07
$5.41B mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryNeuroscience and Psychiatry Therapies
AboutScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Show more
  • Revenue$0
  • EBITDA-$383M-53.1%
  • Net Income-$378M-53.5%
  • EPS (Diluted)-3.29-33.2%
  • ROE-123.08%-48.4%
  • ROIC-201.2%-134.7%
  • Debt/Equity0.44+151.1%
  • Interest Coverage-53.83-53.7%
Technical→

SRRK Key Insights

Scholar Rock Holding Corporation (SRRK) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

  • ✗Profits declining 34.3% over 5 years
  • ✗Weak Piotroski F-Score: 1/9
  • ✗Shares diluted 14.9% in last year
  • ✗Expensive at 22.0x book value
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

SRRK Price & Volume

Scholar Rock Holding Corporation (SRRK) stock price & volume — 10-year historical chart

Loading chart...

SRRK Growth Metrics

Scholar Rock Holding Corporation (SRRK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-53.45%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-30.56%

Return on Capital

10 Years-55%
5 Years-63.93%
3 Years-75.83%
Last Year-99.03%

SRRK Recent Earnings

Scholar Rock Holding Corporation (SRRK) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
Mar 3, 2026
EPS
$0.88
Est $0.88
+0.3%
Revenue
—
Est $2M
Q4 2025
Nov 14, 2025
EPS
$0.90
Est $0.84
-7.8%
Revenue
—
Est $50,000
Q3 2025
Aug 6, 2025
EPS
$0.98
Est $0.66
-48.5%
Revenue
—
Est $55,560
Q2 2025
May 14, 2025
EPS
$0.67
Est $0.63
-6.3%
Revenue
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMar 3, 2026
$0.88vs $0.88+0.3%
—vs $2M
Q4 2025Nov 14, 2025
$0.90vs $0.84-7.8%
—vs $50,000
Q3 2025Aug 6, 2025
$0.98vs $0.66-48.5%
—vs $55,560
Q2 2025May 14, 2025
$0.67vs $0.63-6.3%
—
Based on last 12 quarters of dataView full earnings history →

SRRK Peer Comparison

Scholar Rock Holding Corporation (SRRK) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
KYMR logoKYMRKymera Therapeutics, Inc.Direct Competitor7.04B86.26-23.38-16.72%-6.12%-25.02%0.05
ARQT logoARQTArcutis Biotherapeutics, Inc.Direct Competitor3.02B24.17-185.9291.34%-0.57%-1.41%0.03
IMVT logoIMVTImmunovant, Inc.Direct Competitor5.83B28.67-10.50-47.07%0.00
ACVA logoACVAACV Auctions Inc.Direct Competitor908.97M5.22-13.3819.22%-7.97%-14.27%0.44
MDGL logoMDGLMadrigal Pharmaceuticals, Inc.Direct Competitor12.38B539.73-42.00432.05%-27.32%-50.15%0.59
PRTA logoPRTAProthena Corporation plcDirect Competitor601.85M11.18-2.47-92.84%-25.21%-73%0.05
BIIB logoBIIBBiogen Inc.Product Competitor28.15B190.6821.591.39%13.92%7.55%0.38
IONS logoIONSIonis Pharmaceuticals, Inc.Product Competitor12.7B76.85-32.2933.87%-30.87%-58.57%5.35

Compare SRRK vs Peers

Scholar Rock Holding Corporation (SRRK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs KYMR

Most directly comparable listed peer for SRRK.

Scale Benchmark

vs LLY

Larger-name benchmark to compare SRRK against a more recognizable public peer.

Peer Set

Compare Top 5

vs KYMR, ARQT, IMVT, ACVA

SRRK Income Statement

Scholar Rock Holding Corporation (SRRK) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Sales/Revenue0020.49M15.4M18.82M33.19M000
Revenue Growth %-100%---24.83%22.16%76.41%-100%--
Cost of Goods Sold669K807K54.22M74.06M108.47M123.04M2.84M1.94M1.66M
COGS % of Revenue--264.58%480.83%576.47%370.69%---
Gross Profit
-669K▲ 0%
-807K▼ 20.6%
-33.73M▼ 4079.1%
-58.66M▼ 73.9%
-89.65M▼ 52.8%
-89.85M▼ 0.2%
-2.84M▲ 96.8%
-1.94M▲ 31.9%
-1.66M▲ 14.4%
Gross Margin %---164.58%-380.83%-476.47%-270.69%---
Gross Profit Growth %94.47%-20.63%-4079.06%-73.93%-52.84%-0.22%96.83%31.89%14.4%
Operating Expenses25.03M50.69M20.82M28.22M40.27M44.52M168.45M250.12M382.99M
OpEx % of Revenue--101.59%183.2%214.01%134.12%---
Selling, General & Admin5.08M14.38M20.82M28.22M40.27M42.62M49.4M67.5M176.21M
SG&A % of Revenue--101.59%183.2%214.01%128.4%---
Research & Development19.94M36.31M54.22M74.06M108.47M124.44M119.06M182.61M206.78M
R&D % of Revenue--264.58%480.83%576.47%374.91%---
Other Operating Expenses-10K-56K-54.22M-74.06M-108.47M-122.54M000
Operating Income
-25.03M▲ 0%
-50.69M▼ 102.5%
-54.54M▼ 7.6%
-86.88M▼ 59.3%
-129.92M▼ 49.5%
-134.37M▼ 3.4%
-171.29M▼ 27.5%
-252.05M▼ 47.1%
-384.64M▼ 52.6%
Operating Margin %---266.16%-564.03%-690.48%-404.81%---
Operating Income Growth %-54.4%-102.53%-7.59%-59.29%-49.54%-3.43%-27.48%-47.15%-52.6%
EBITDA-24.36M-49.88M-53.24M-85.39M-127.29M-131.38M-168.45M-250.12M-382.99M
EBITDA Margin %---259.8%-554.35%-676.52%-395.82%---
EBITDA Growth %-55.8%-104.78%-6.72%-60.38%-49.08%-3.21%-28.21%-48.48%-53.12%
D&A (Non-Cash Add-back)669K807K1.3M1.49M2.63M2.99M2.84M1.94M1.66M
EBIT-25.03M-50.69M-54.54M-86.88M-129.92M-132.47M-165.79M-239.46M-371.05M
Net Interest Income00000005.84M7.01M
Interest Income01.42M0000012.68M13.9M
Interest Expense00000006.84M6.89M
Other Income/Expense34K1.37M3.54M395K-1.88M-132K5.51M5.76M6.71M
Pretax Income
-25M▲ 0%
-49.33M▼ 97.3%
-51M▼ 3.4%
-86.48M▼ 69.6%
-131.8M▼ 52.4%
-134.5M▼ 2.1%
-165.79M▼ 23.3%
-246.29M▼ 48.6%
-377.94M▼ 53.5%
Pretax Margin %---248.88%-561.47%-700.46%-405.21%---
Income Tax-44K00000000
Effective Tax Rate %0.18%0%0%0%0%0%0%0%0%
Net Income
-25M▲ 0%
-49.33M▼ 97.3%
-51M▼ 3.4%
-86.48M▼ 69.6%
-131.8M▼ 52.4%
-134.5M▼ 2.1%
-165.79M▼ 23.3%
-246.29M▼ 48.6%
-377.94M▼ 53.5%
Net Margin %---248.88%-561.47%-700.46%-405.21%---
Net Income Growth %-54.22%-97.34%-3.39%-69.57%-52.4%-2.05%-23.26%-48.56%-53.45%
Net Income (Continuing)-25M-49.33M-51M-86.48M-131.8M-134.5M-165.79M-246.29M-377.94M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)
-1.40▲ 0%
-3.15▼ 125.0%
-1.80▲ 42.9%
-2.77▼ 53.9%
-3.59▼ 29.6%
-2.21▲ 38.4%
-1.99▲ 10.0%
-2.47▼ 24.1%
-3.29▼ 33.2%
EPS Growth %-53.85%-125%42.86%-53.89%-29.6%38.44%9.95%-24.12%-33.2%
EPS (Basic)-1.40-3.15-1.80-2.77-3.59-2.21-1.99-2.47-3.29
Diluted Shares Outstanding17.91M15.66M27.54M30.73M36.71M59.61M75.98M99.84M114.7M
Basic Shares Outstanding17.91M15.66M27.54M30.73M36.71M59.61M75.98M99.84M114.7M
Dividend Payout Ratio---------

SRRK Balance Sheet

Scholar Rock Holding Corporation (SRRK) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Total Current Assets59.2M177.94M185.17M344.4M265.32M328.02M288.19M451.17M385.15M
Cash & Short-Term Investments57.96M175.65M157.45M341.03M252.99M315.36M279.94M437.28M367.56M
Cash Only56.46M115.07M36.31M160.36M212.84M103.28M101.86M177.88M323.53M
Short-Term Investments1.5M60.58M121.14M180.67M40.16M212.09M178.08M259.4M44.04M
Accounts Receivable0025M002.73M1.08M2.15M0
Days Sales Outstanding--445.3--30.07---
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets02.3M2.72M012.32M00017.58M
Total Non-Current Assets2.44M3.4M11.21M43.9M39.13M30.14M22.84M23.76M19.13M
Property, Plant & Equipment2.18M3.19M8.62M40.38M35.01M25.93M16.02M18.41M12.09M
Fixed Asset Turnover--2.38x0.38x0.54x1.28x---
Goodwill000000000
Intangible Assets0000004.07M2.4M0
Long-Term Investments205K205K2.5M02.5M0000
Other Non-Current Assets50K098K3.52M1.62M4.22M2.75M2.96M7.04M
Total Assets
61.64M▲ 0%
181.34M▲ 194.2%
196.38M▲ 8.3%
388.31M▲ 97.7%
304.44M▼ 21.6%
358.17M▲ 17.6%
311.04M▼ 13.2%
474.92M▲ 52.7%
404.27M▼ 14.9%
Asset Turnover--0.10x0.04x0.06x0.09x---
Asset Growth %88.02%194.2%8.3%97.73%-21.6%17.65%-13.16%52.69%-14.88%
Total Current Liabilities5.02M31.12M32.81M42.56M64.3M36.39M32.74M46.94M55.42M
Accounts Payable1.36M3.3M1.13M3.41M4.43M3.99M3.46M10.1M10.3M
Days Payables Outstanding741.461.49K7.6116.814.9211.85444.71.9K2.27K
Short-Term Debt641K424K1.14M08.98M01.33M05.55M
Deferred Revenue (Current)-641K20.21M20.92M18.82M33.19M0000
Other Current Liabilities1.85M30K5.25M15K3.13M222K85K039.57M
Current Ratio11.78x5.72x5.64x8.09x4.13x9.01x8.80x9.61x6.95x
Quick Ratio11.78x5.72x5.64x8.09x4.13x9.01x8.80x9.61x6.95x
Cash Conversion Cycle---------
Total Non-Current Liabilities110.14M43.59M50.67M84.97M68.07M61.54M53.08M59.35M103.36M
Long-Term Debt398K24K024.68M48.42M49.74M48.68M50.15M103.36M
Capital Lease Obligations004.17M27.09M19.65M11.8M4.39M9.21M0
Deferred Tax Liabilities0-42.72M0000000
Other Non-Current Liabilities109.74M871K9K5K00000
Total Liabilities115.16M74.71M83.48M127.53M132.37M97.93M85.82M106.29M158.78M
Total Debt1.04M462K5.3M57.14M84.47M69.4M61.82M65.13M108.92M
Net Debt-55.42M-114.61M-31M-103.22M-128.37M-33.88M-40.04M-112.75M-214.61M
Debt / Equity-0.00x0.05x0.22x0.49x0.27x0.27x0.18x0.44x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage--------35.02x-53.83x
Total Equity
-53.52M▲ 0%
106.62M▲ 299.2%
112.9M▲ 5.9%
260.77M▲ 131.0%
172.07M▼ 34.0%
260.24M▲ 51.2%
225.22M▼ 13.5%
368.63M▲ 63.7%
245.49M▼ 33.4%
Equity Growth %-78.25%299.21%5.89%130.97%-34.01%51.23%-13.46%63.68%-33.41%
Book Value per Share-2.996.814.108.484.694.372.963.692.14
Total Shareholders' Equity-53.52M106.62M112.9M260.77M172.07M260.24M225.22M368.63M245.49M
Common Stock4K26K30K34K35K52K76K94K108K
Retained Earnings-57.52M-106.85M-157.85M-244.33M-376.13M-510.63M-676.42M-922.72M-1.3B
Treasury Stock5K00000000
Accumulated OCI-2K-8K37K-2K-35K-884K92K160K94K
Minority Interest000000000

SRRK Cash Flow Statement

Scholar Rock Holding Corporation (SRRK) cash flow — operating, investing & free cash flow history

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Cash from Operations-21.74M24.57M-63.12M-60.27M-126.79M-132.69M-145.23M-200.95M-300.04M
Operating CF Margin %---308%-391.29%-673.84%-399.76%---
Operating CF Growth %-43.56%213.04%-356.87%4.51%-110.36%-4.66%-9.44%-38.37%-49.31%
Net Income-25M-49.33M-51M-86.48M-131.8M-134.5M-165.79M-246.29M-377.94M
Depreciation & Amortization669K807K1.3M1.49M2.63M2.99M2.84M1.94M1.66M
Stock-Based Compensation1.48M5.21M7.97M11.18M23.15M27.7M27.14M36.63M75.6M
Deferred Taxes-199K272K176K000000
Other Non-Cash Items-162K-289K-401K2.3M7.67M5.51M1.19M186K1.7M
Working Capital Changes1.47M67.9M-21.16M11.24M-28.44M-34.39M-10.61M6.59M-1.05M
Change in Receivables00-25M25M00000
Change in Inventory000000000
Change in Payables636K1.66M-1.34M2.1M1.02M-251K-529K6.63M208K
Cash from Investing17.66M-60.23M-62.24M-63.5M134.31M-171.7M41.14M-76.06M218.69M
Capital Expenditures-361K-1.49M-3.12M-4.09M-5.25M-1.06M-71K-98K-602K
CapEx % of Revenue--15.2%26.54%27.89%3.21%---
Acquisitions000000000
Investments---------
Other Investing18.03M-58.74M8K00013K00
Cash from Financing50.5M94.27M48.88M247.82M44.95M194.83M102.57M353.03M228.4M
Debt Issued (Net)-667K-667K-365K24.62M24.98M-975K0049.14M
Equity Issued (Net)46.89M048.35M215.92M13.1M195.31M97.71M324.41M179.26M
Dividends Paid000000000
Share Repurchases000000000
Other Financing4.28M94.94M900K7.28M6.87M492K4.87M28.61M0
Net Change in Cash
46.43M▲ 0%
58.61M▲ 26.2%
-76.47M▼ 230.5%
124.05M▲ 262.2%
52.48M▼ 57.7%
-109.56M▼ 308.8%
-1.51M▲ 98.6%
76.02M▲ 5131.3%
147.05M▲ 93.4%
Free Cash Flow
-22.1M▲ 0%
23.08M▲ 204.4%
-66.23M▼ 387.0%
-64.36M▲ 2.8%
-132.04M▼ 105.2%
-133.76M▼ 1.3%
-145.3M▼ 8.6%
-201.05M▼ 38.4%
-300.64M▼ 49.5%
FCF Margin %---323.2%-417.83%-701.73%-402.97%---
FCF Growth %-38.68%204.44%-386.97%2.83%-105.16%-1.3%-8.63%-38.37%-49.54%
FCF per Share-1.231.47-2.41-2.09-3.60-2.24-1.91-2.01-2.62
FCF Conversion (FCF/Net Income)0.87x-0.50x1.24x0.70x0.96x0.99x0.88x0.82x0.79x
Interest Paid000000000
Taxes Paid000000000

SRRK Key Ratios

Scholar Rock Holding Corporation (SRRK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)---185.78%-46.46%-46.29%-60.9%-62.22%-68.3%-82.95%-123.08%
Return on Invested Capital (ROIC)----110.69%-54.42%-96.83%-74.63%-62.43%-85.72%-201.2%
Gross Margin-3192.08%---164.58%-380.83%-476.47%-270.69%---
Net Margin-4276.25%---248.88%-561.47%-700.46%-405.21%---
Debt / Equity--0.00x0.05x0.22x0.49x0.27x0.27x0.18x0.44x
Interest Coverage-853.16x--------35.02x-53.83x
FCF Conversion0.93x0.87x-0.50x1.24x0.70x0.96x0.99x0.88x0.82x0.79x
Revenue Growth--100%---24.83%22.16%76.41%-100%--

SRRK SEC Filings & Documents

Scholar Rock Holding Corporation (SRRK) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Mar 31, 2026·SEC

Material company update

Mar 3, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 3, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Mar 19, 2024·SEC

10-Q Quarterly Reports

6
FY 2025

Nov 14, 2025·SEC

FY 2025

Aug 6, 2025·SEC

FY 2025

May 14, 2025·SEC

SRRK Frequently Asked Questions

Scholar Rock Holding Corporation (SRRK) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Scholar Rock Holding Corporation (SRRK) grew revenue by 0.0% over the past year. Growth has been modest.

Scholar Rock Holding Corporation (SRRK) reported a net loss of $377.9M for fiscal year 2025.

Dividend & Returns

Scholar Rock Holding Corporation (SRRK) has a return on equity (ROE) of -123.1%. Negative ROE indicates the company is unprofitable.

Scholar Rock Holding Corporation (SRRK) had negative free cash flow of $300.6M in fiscal year 2025, likely due to heavy capital investments.

Explore More SRRK

Scholar Rock Holding Corporation (SRRK) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.